Pantoprazole Does Not Influence the Antiplatelet Effect of Clopidogrel-A Whole Blood Aggregometry Study After Coronary Stenting

Mehta, 2001, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study., Lancet, 358, 527, 10.1016/S0140-6736(01)05701-4

Steinhubl, 2002, Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial., JAMA, 288, 2411, 10.1001/jama.288.19.2411

Savi, 2000, Identification and biological activity of the active metabolite of clopidogrel., Thromb Haemost, 84, 891, 10.1055/s-0037-1614133

Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects., Blood, 108, 2244, 10.1182/blood-2006-04-013052

Lau, 2004, Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance., Circulation, 109, 166, 10.1161/01.CIR.0000112378.09325.F9

Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity., Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83

Marcucci, 2009, Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up., Circulation, 119, 237, 10.1161/CIRCULATIONAHA.108.812636

Patti, 2008, Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study., J Am Coll Cardiol, 52, 1128, 10.1016/j.jacc.2008.06.038

Maree, 2007, Variable platelet response to aspirin and clopidogrel in atherothrombotic disease., Circulation, 115, 2196, 10.1161/CIRCULATIONAHA.106.675991

Angiolillo, 2007, Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives., J Am Coll Cardiol, 49, 1505, 10.1016/j.jacc.2006.11.044

Kim, 2008, The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance., Clin Pharmacol Ther, 84, 236, 10.1038/clpt.2008.20

Mega, 2009, Cytochrome p-450 polymorphisms and response to clopidogrel., N Engl J Med, 360, 354, 10.1056/NEJMoa0809171

Simon, 2009, Genetic determinants of response to clopidogrel and cardiovascular events., N Engl J Med, 360, 363, 10.1056/NEJMoa0808227

Trenk, 2008, Cytochrome P450 2C19 681GA polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents., J Am Coll Cardiol, 51, 1925, 10.1016/j.jacc.2007.12.056

Cuisset, 2009, Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study., J Am Coll Cardiol, 54, 1149, 10.1016/j.jacc.2009.05.050

Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study., J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064

Gilard, 2006, Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin., J Thromb Haemost, 4, 2508, 10.1111/j.1538-7836.2006.02162.x

Ho, 2009, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome., JAMA, 301, 937, 10.1001/jama.2009.261

Juurlink, 2009, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel., CMAJ, 180, 713, 10.1503/cmaj.082001

ODonoghue, 2009, Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials., Lancet, 374, 989, 10.1016/S0140-6736(09)61525-7

Sibbing, 2009, Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel., Thromb Haemost, 101, 714, 10.1160/TH08-12-0808

Small, 2008, Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel., J Clin Pharmacol, 48, 475, 10.1177/0091270008315310

Zuern, 2010, Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy., Thromb Res, 125, e51, 10.1016/j.thromres.2009.08.016

Andersson, 1993, Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism., Br J Clin Pharmacol, 36, 521, 10.1111/j.1365-2125.1993.tb00410.x

Howden, 1991, Clinical pharmacology of omeprazole., Clin Pharmacokinet, 20, 38, 10.2165/00003088-199120010-00003

Radhofer-Welte, 1999, Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man., Drugs Today (Barc), 35, 765, 10.1358/dot.1999.35.10.561695

Rassen, 2009, Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome., Circulation, 120, 2322, 10.1161/CIRCULATIONAHA.109.873497

Bhatt, 2008, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents., J Am Coll Cardiol, 52, 1502, 10.1016/j.jacc.2008.08.002

Ivandic, 2006, Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor., Clin Chem, 52, 383, 10.1373/clinchem.2005.059535

Neubauer, 2008, How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification., Thromb Haemost, 99, 357, 10.1160/TH07-10-0624

Kwok, 2010, Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel., Aliment Pharmacol Ther, 31, 810, 10.1111/j.1365-2036.2010.04247.x

Geisler, 2008, The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score., J Thromb Haemost, 6, 54, 10.1111/j.1538-7836.2007.02812.x

Blume, 2006, Pharmacokinetic drug interaction profiles of proton pump inhibitors., Drug Saf, 29, 769, 10.2165/00002018-200629090-00002

Andersson, 2001, Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole., Clin Pharmacokinet, 40, 523, 10.2165/00003088-200140070-00004

Humphries, 1999, Review article: drug interactions with agents used to treat acid-related diseases., Aliment Pharmacol Ther, 13, 18, 10.1046/j.1365-2036.1999.00021.x

Cheer, 2003, Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders., Drugs, 63, 101, 10.2165/00003495-200363010-00006

Rebello, 2000, Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists., J Thromb Thrombolysis, 9, 23, 10.1023/A:1018679708251

Neubauer, 2006, Thienopyridines and statins: assessing a potential drug-drug interaction., Curr Pharm Des, 12, 1271, 10.2174/138161206776361354